184 related articles for article (PubMed ID: 35933523)
1. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.
Zuna J; Hovorkova L; Krotka J; Koehrmann A; Bardini M; Winkowska L; Fronkova E; Alten J; Koehler R; Eckert C; Brizzolara L; Trkova M; Stuchly J; Zimmermann M; De Lorenzo P; Valsecchi MG; Conter V; Stary J; Schrappe M; Biondi A; Trka J; Zaliova M; Cazzaniga G; Cario G
Leukemia; 2022 Dec; 36(12):2793-2801. PubMed ID: 35933523
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of childhood ALL using
Hovorkova L; Zaliova M; Venn NC; Bleckmann K; Trkova M; Potuckova E; Vaskova M; Linhartova J; Machova Polakova K; Fronkova E; Muskovic W; Giles JE; Shaw PJ; Cario G; Sutton R; Stary J; Trka J; Zuna J
Blood; 2017 May; 129(20):2771-2781. PubMed ID: 28331056
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
Roberts KG; Pei D; Campana D; Payne-Turner D; Li Y; Cheng C; Sandlund JT; Jeha S; Easton J; Becksfort J; Zhang J; Coustan-Smith E; Raimondi SC; Leung WH; Relling MV; Evans WE; Downing JR; Mullighan CG; Pui CH
J Clin Oncol; 2014 Sep; 32(27):3012-20. PubMed ID: 25049327
[TBL] [Abstract][Full Text] [Related]
6. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
8. High frequency of BTG1 deletions in patients with BCR-ABL1-positive acute leukemia.
Xie J; Wang Q; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Cancer Genet; 2014 May; 207(5):226-30. PubMed ID: 24998463
[TBL] [Abstract][Full Text] [Related]
9. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
10. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
Pagani IS; Dang P; Saunders VA; Grose R; Shanmuganathan N; Kok CH; Carne L; Rwodzi Z; Watts S; McLean J; Braley J; Altamura H; Yeung DT; Branford S; Yong ASM; White DL; Hughes TP; Ross DM
Leukemia; 2020 Apr; 34(4):1052-1061. PubMed ID: 31768016
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
[TBL] [Abstract][Full Text] [Related]
12. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
13. Interphase FISH for BCR-ABL1 rearrangement on neutrophils: A decisive tool to discriminate a lymphoid blast crisis of chronic myeloid leukemia from a de novo BCR-ABL1 positive acute lymphoblastic leukemia.
Balducci E; Loosveld M; Rahal I; Boudjarane J; Alazard E; Missirian C; Lafage-Pochitaloff M; Michel G; Zattara H
Hematol Oncol; 2018 Feb; 36(1):344-348. PubMed ID: 28444777
[TBL] [Abstract][Full Text] [Related]
14. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
15. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
[TBL] [Abstract][Full Text] [Related]
16. p190 BCR-ABL rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia.
Lemes A; Gómez Casares MT; de la Iglesia S; Matutes E; Molero MT
Cancer Genet Cytogenet; 1999 Aug; 113(1):100-2. PubMed ID: 10459357
[TBL] [Abstract][Full Text] [Related]
17. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract][Full Text] [Related]
18.
Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone.
Behrens YL; Schienke A; Davenport C; Lentes J; Tauscher M; Steinemann D; Rasche M; Knirsch S; Joachim S; Reinhardt D; Schlegelberger B; Göhring G
Cancer Genet; 2021 Jun; 254-255():70-74. PubMed ID: 33647814
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
